Limits...
Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: a patient-centered evaluation.

Schaefer C, Mann R, Sadosky A, Daniel S, Parsons B, Nieshoff E, Tuchman M, Nalamachu S, Anschel A, Stacey BR - Pain Med (2014)

Bottom Line: Patient-reported outcomes (health status, physical and mental health, pain interference with function, sleep, anxiety, and depression) were significantly worse among subjects with greater pain severity (all P < 0.0001).Severe pain subjects were negatively impacted by ≥30% in each outcome compared with mild pain subjects; standardized effect size was moderate for anxiety (0.59) and large (>0.95) for all others.Subjects across NeP conditions exhibited high pain levels, which were significantly associated with poor function, compromised health status and sleep, and increased anxiety and depression.

View Article: PubMed Central - PubMed

Affiliation: Covance Market Access Services Inc., Gaithersburg, Maryland, USA.

Show MeSH

Related in: MedlinePlus

NeP subjects reported a variety of comorbid conditions*.*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. A significant difference was observed across pain severity levels for depressive symptoms (P < 0.0001), sleep disturbance/insomnia (P = 0.0037), anxiety (P = 0.0003), headache/migraine (P < 0.0001), cognitive dysfunction (P = 0.0491), restless leg syndrome (P = 0.0001), chronic fatigue syndrome (P = 0.0019), and fibromyalgia (P = 0.0008).BPI-SF = Brief Pain Inventory-Short Form; NeP = neuropathic pain. [Color figure can be viewed in the online issue, which is available at http://wileyonlinelibrary.com.]
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4491355&req=5

fig02: NeP subjects reported a variety of comorbid conditions*.*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. A significant difference was observed across pain severity levels for depressive symptoms (P < 0.0001), sleep disturbance/insomnia (P = 0.0037), anxiety (P = 0.0003), headache/migraine (P < 0.0001), cognitive dysfunction (P = 0.0491), restless leg syndrome (P = 0.0001), chronic fatigue syndrome (P = 0.0019), and fibromyalgia (P = 0.0008).BPI-SF = Brief Pain Inventory-Short Form; NeP = neuropathic pain. [Color figure can be viewed in the online issue, which is available at http://wileyonlinelibrary.com.]

Mentions: Overall, the mean (SD) time since NeP diagnosis was 7.8 (6.8) years, with a longer duration of NeP observed among those with greater pain severity (P = 0.0059). On average, the time from appearance of NeP symptoms to diagnosis was 20 months (1.7 years). Approximately three-fourths of the sample reported being originally diagnosed by a primary care physician (39.3%), a neurologist (23.9%), or a pain specialist (11.4%) (data not shown). On average, subjects had approximately 3 comorbidities, with more comorbidities among those with greater pain severity (P < 0.0001). The most common comorbidities overall were depressive symptoms (42.6%), sleep disturbance/insomnia (42.1%), and anxiety (35.1%) (Figure 2). Seventy-four (11.9%) subjects were not able to walk on their own; 50 of these subjects were SCI-NeP subjects.


Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: a patient-centered evaluation.

Schaefer C, Mann R, Sadosky A, Daniel S, Parsons B, Nieshoff E, Tuchman M, Nalamachu S, Anschel A, Stacey BR - Pain Med (2014)

NeP subjects reported a variety of comorbid conditions*.*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. A significant difference was observed across pain severity levels for depressive symptoms (P < 0.0001), sleep disturbance/insomnia (P = 0.0037), anxiety (P = 0.0003), headache/migraine (P < 0.0001), cognitive dysfunction (P = 0.0491), restless leg syndrome (P = 0.0001), chronic fatigue syndrome (P = 0.0019), and fibromyalgia (P = 0.0008).BPI-SF = Brief Pain Inventory-Short Form; NeP = neuropathic pain. [Color figure can be viewed in the online issue, which is available at http://wileyonlinelibrary.com.]
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4491355&req=5

fig02: NeP subjects reported a variety of comorbid conditions*.*Scores on the BPI-SF Pain Severity Index were used to classify average pain severity. Ten subjects did not respond to all required items needed to calculate a BPI-SF average pain severity score and thus were not included in any analysis by pain severity category. A significant difference was observed across pain severity levels for depressive symptoms (P < 0.0001), sleep disturbance/insomnia (P = 0.0037), anxiety (P = 0.0003), headache/migraine (P < 0.0001), cognitive dysfunction (P = 0.0491), restless leg syndrome (P = 0.0001), chronic fatigue syndrome (P = 0.0019), and fibromyalgia (P = 0.0008).BPI-SF = Brief Pain Inventory-Short Form; NeP = neuropathic pain. [Color figure can be viewed in the online issue, which is available at http://wileyonlinelibrary.com.]
Mentions: Overall, the mean (SD) time since NeP diagnosis was 7.8 (6.8) years, with a longer duration of NeP observed among those with greater pain severity (P = 0.0059). On average, the time from appearance of NeP symptoms to diagnosis was 20 months (1.7 years). Approximately three-fourths of the sample reported being originally diagnosed by a primary care physician (39.3%), a neurologist (23.9%), or a pain specialist (11.4%) (data not shown). On average, subjects had approximately 3 comorbidities, with more comorbidities among those with greater pain severity (P < 0.0001). The most common comorbidities overall were depressive symptoms (42.6%), sleep disturbance/insomnia (42.1%), and anxiety (35.1%) (Figure 2). Seventy-four (11.9%) subjects were not able to walk on their own; 50 of these subjects were SCI-NeP subjects.

Bottom Line: Patient-reported outcomes (health status, physical and mental health, pain interference with function, sleep, anxiety, and depression) were significantly worse among subjects with greater pain severity (all P < 0.0001).Severe pain subjects were negatively impacted by ≥30% in each outcome compared with mild pain subjects; standardized effect size was moderate for anxiety (0.59) and large (>0.95) for all others.Subjects across NeP conditions exhibited high pain levels, which were significantly associated with poor function, compromised health status and sleep, and increased anxiety and depression.

View Article: PubMed Central - PubMed

Affiliation: Covance Market Access Services Inc., Gaithersburg, Maryland, USA.

Show MeSH
Related in: MedlinePlus